

April 23, 2025

To,
The Chief General Manager
Listing Operation,
BSE Limited,
20th Floor, P. J. Towers,
Dalal Street,
Mumbai – 400 001.
Scrip Code: 524743

Dear Sir/ Madam,

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Further to our letter dated January 03, 2025, we hereby inform that Ministry of Corporate Affairs vide its letter dated April 22, 2025 has conveyed its approval for appointment of Mr. Ravindran Govindan (DIN: 03137661) as Managing Director of the Company for a period of 5 years with effect from January 31, 2025.

Details of Mr. Ravindran Govindan along with the disclosures required in terms of SEBI Circular No. CIR/CFD/ CMD/ 4/2015 dated September 9, 2015 is annexed herewith.

We request you to take note of the above and bring this to the notice of all concerned

Thanking You,
Yours Truly,

For **FISCHER MEDICAL VENTURES LIMITED**
(Formerly known as Fischer Chemic Limited)



ARAVINDKUMAR V
COMPANY SECRETARY & COMPLIANCE OFFICER

ANNEXURE – I

Details under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.

Name	Ravindran Govindan
DIN	03137661
Reason for Change	Appointment of Mr. Ravindran Govindan (DIN: 03137661) as Chairman & Managing Director of the Company for a period of 5 years, from January 31, 2025 upto January 30, 2030 (both days included)
Brief profile (in case of appointment)	Enclosed Below
Disclosure of relationships between Directors	Not related with any Director

PROFILE OF RAVINDRAN GOVINDAN

Mr. Ravi, a trailblazer whose journey epitomizes the convergence of law, entrepreneurship, and visionary leadership. Graduating from the prestigious National University of Singapore with a degree in law, Mr. Ravi swiftly ascended the ranks of the legal world, wielding his expertise as a solicitor in the esteemed Supreme Court of Singapore and transforming his own law practice into a thriving multi-partnership firm. Mr. Ravi's ventures transcended traditional boundaries as he ventured into diverse realms, from spearheading property developments across the Asia Pacific to orchestrating high-stakes IPOs on the Australia and Singapore stock exchanges. Notably, he played a pivotal role in the privatization of Myanmar Airlines, leaving an indelible mark on the aviation industry.

Armed with 45 years of real-world expertise in building companies from the ground up, Mr. Ravi embarked on a new chapter in 2006, founding Mercatus Capital. As the architect of this private equity venture firm, he champions budding entrepreneurs in the realm of emerging technologies, offering a gamut of services from seed funding to corporate restructuring. His astute guidance has propelled startups to new heights, igniting innovation and fostering growth in dynamic sectors.

Mr. Ravi has a strong passion for healthcare innovation from his tenure at Fisher Scientific Inc. as Executive Chairman and President for the Asia Pacific, where he managed billion-dollar budgets, to his trailblazing initiatives driving technological advancements and pioneering novel solutions & innovations in healthcare, leading to improved patient outcomes and cost-efficiency.

As a luminary in the entrepreneurial ecosystem, Mr. Ravi extends his expertise as a trusted advisor to private and public enterprises, as well as influential individuals in the region, including Latona Associates Inc. – a private investment and financial firm based in New York. In every endeavour, Mr. Ravi epitomizes resilience, innovation, and unwavering dedication, leaving an indelible imprint on the global business landscape.
